Pre-register for Imunon’s virtual presentation at the Virtual Investor Conferences site HERE. This will be a live, interactive online event where investors are invited to ask the Company questions in ...

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

Interleukin(IL)-17A, an inflammatory cytokine, has been implicated in atherosclerosis, in which inflammatory cells within atherosclerotic plaques express IL-17A. However, its role in the development ...

Researchers developed a nanoparticle method to deliver thymoquinone from black seed for treating cryptosporidiosis. This ...

Chronic allergic inflammation affects brain chemistry and mood regulation through cytokine dysregulation, increased blood-brain barrier permeability, and neurotransmitter system interference, Gary ...

Background The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

dCentre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK eWellcome-Wolfson Institute for ...

interleukin-6; NA, data not available; NIHSS, National Institutes for Health Stroke Scale; OXVASC, Oxford Vascular Study; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; REGITELL, ...

To evaluate the safety of sequentially administered recombinant (r) human (h) interleukin-12 (IL-12) and interferon alfa-2b (IFN-α-2b) in patients with advanced cancer and to determine the effects of ...

IDA was determined by assaying the salivary hepcidin levels using an ELISA kit, while expression of hepcidin, hepcidin inducer IL-6, Interferon I (IFN I) and IFN-γ were determined by qPCR. IDA can ...

There were some other treatments, such as interferon and interleukin, that had very marginal benefit with a lot of [adverse events], and unfortunately, [most patients] who had melanoma that had spread ...